A Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cell, NVSI-06-09) and Inactivated COVID-19 Vaccine (Vero Cell)

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
A total of 516 healthy subjects aged 18 years and above who have been vaccinated with 2 doses/3 doses of inactivated COVID-19 vaccine, will be enrolled, and randomly assigned to experimental group and control group in a 1:1 ratio, with 258 subjects in each sequential group.
Epistemonikos ID: b0de62bb44890d052c9bfcc0d40cc81fff8dc248
First added on: Mar 25, 2022